RETRACTED

Study the association among some novel biomarker in acute leukemia patients

Dhuha Salman Aljuboory[1*] and *Intisar Razzaq* Sharba [2]

[1]Babylon University, Al Hillah, Iraq
[2]Kufa University, Kufa, Iraq

Abstract: Acute leukemia (ALL and AML) has an adverse effect hemostasis. Coagulopathy is a common comorbidity in patients with acute leukemia. When compared patients with control the result showed highly significant (p-value<0.05) increase in acute leukemia patients as compared control group in mean of PDGF-BB level , ANXA level, D-Dimer level, H3 . Comparison characteristic parameter between acute leukemia patients groups founded significant increase in age, PDGF-BB, D-Dimer and ANXA2 in AML patients more than ALL patients group. H3 and showed no significant difference between AML and ALL patients groups. The ROC curve analysis and AUC for study biomarkers to diagnosis between acute leukemia patients group showed highly positive significant (p-value <0.05) predictive value with PGDF-BB followed by D-Dimer, ANXA2 then H3

1 Introduction

Acute leukemia's represent neoplasm of the hematopoietic cell precursors manifested as clonal expansion of myeloid and lymphoid hematopoiesis [1]. Acute leukemia can be broadly classified into ALL and AML depending on the type of cell lineage affected. ALL is the most common malignancy diagnosed in children. It is clinically and morphologically heterogeneous [2, 3]. AML refers to a group of hematological malignancies that arise within bone marrow precursors of myeloid, monocyte, erythroid and megakaryotic cell lineages. French, American and British (FAB) classification system divides Acute Myelogenous Leukemia into M-0 to M-7 sub-types [4] . Hemostatic complications due to coagulopathy are one of the leading causes of mortality in patients with acute leukemia [5]. Histones, the most abundant proteins in the nucleus, comprise linker histone H1 and core histones H2A, H2B, H3, and H4. Histones are released into the extracellular space [6], where they induce platelet aggregation [7] endothelial damage [8] and cardiac injury [9]. Circulating histones were toxic toward vascular endothelial cells [8], cardiomyocytes [10], caused microvascular thrombosis and myocardial dysfunction. The extracellular histones 3 were associated with coagulopathy mediate these pathological effects by being cytotoxic for nucleated cells, such as endothelial and epithelial cells [9] and by promoting platelet activation with resultant thrombosis and acute thrombocytopenia [11].

* Corresponding author: Dhuhaaljuboory@gmail.com

© The Authors, published by EDP Sciences. This is an open access article distributed under the terms of the Creative Commons Attribution License 4.0 (https://creativecommons.org/licenses/by/4.0/).

Annexin A 2 (ANXA2) is a calcium-regulated, phospholipid-binding protein on endothelial cells, macrophages, and some other cells. It is a unique cell surface co-receptor for plasminogen and tissue plasminogen activator (t-PA), and it enhances cell surface plasmin generation [12]. Extracellular and membrane bound Annexin A2 binding directly or indirectly to phosphatidylserine on cells marked for apoptosis, Annexin A2 attends in the engulfment of cells [13]. Membrane bound Annexin A2 contributes to fibrinolysis and has anticoagulation effects and involves binding to t-PA and S100A10, hereby facilitating plasmin production. Furthermore, Annexing A2 seems to impact neo-angiogenesis [13]. Platelet-derived growth factor (PDGF) is composed of two homologous polypeptide chains (A and B), both chains can be produced by platelets, macrophages, and endothelial cells, whereas vascular smooth muscle cell produces only PDFG-A chains [14]. PDGFB expressed in endothelium and platelets, so it is a key cell types in thrombosis development [15]. D-dimer is a marker of fibrinolysis harkening the presence of or risk for thrombosis, and it has been found to be a powerful predictor of thrombosis in solid cancers [16] and AML. According to the work of [17] a D-dimer level ≥4 μg/mL fibrinogen equivalent units (FEU) at time of AML diagnosis has a hazard ratio (HR) of 12.3 in terms of risk of venous or arterial thrombosis in multivariable analysis. Although D-dimer has proved a useful test for thrombosis risk prediction in AML, patients with ALL are at increased risk for venous and arterial thrombotic events [18, 19].

2 Materail and Methods

2.1 Ethical Consideration

It was approved by the Institutional Ethics Committees of the College of Science at the University of Kufa and the Scientific Committee for Research in the Health Department of Najaf.

2.2 Patients

This study included collected 80 of samples acute leukemia patients sample (53 male and 27 female), 32 samples acute myelocytic leukemia AML and 48 samples Acute lymphocytic leukemia, were compared with healthy 50 subject (control group) 23female and 27male. The two groups divided their ages into three categories under 18 years' children, 18-39 years adults and youth and above 40 years older adults [20].The patients and controls without any liver disease or inherited coagulopathies also the patients included the study before taking therapeutic dose or after ending the effect of therapeutic dose. They had attended to the National hospital to oncology and hematology disease in Al-najaf Al-ashraf from April 2022 to November 2022. Informed consent was obtained from all patients.

2.3 Biomarkers Determined

-Human Annexin A2 (ANXA2) (Elabscience):

The concentration of ANXA2 in plasma was detected by using human Enzyme - linked Immunosorbent Assay (ELISA) kit

-Human D-Dimer (BT-Lab):

The concentration of human D-Dimer in plasma was detected by using human Enzyme - linked Immunosorbent Assay (ELISA) kit.

-Human PDGF-BB (Elabscience):

RETRACTED

The concentration of fibrinogen in plasma was detected by using human Enzyme - linked Immunosorbent Assay (ELISA) kit

--Human H3 (BT-Lab):

The concentration of human H3 in plasma was detected by using human Enzyme - linked Immunosorbent Assay (ELISA) kit.

2.4 Statistical analysis

All data were statistical analyzed with software programs SPSS v.28 and Microsoft software excel 2021 for graphic. Normal distribution statistical analysis for the differences between group, and Data are expressed as mean ± SE (standard error). Using of Independent T- tests to compare continuous variables between groups. Correlation coefficient analysis was completed with Pearson's and linear regression. ROC curve analysis and AUC for diagnosis the independent variables. Significance of differences was detected at p<0.05. [21].

3 Results

The statistical analysis in the table (1) indicated to comparison between 80 patients with leukemia's consisted of 53 (66.3%) male and 27 (33.8%) female, compared to 50 healthy participates as controls group, which consisted of 27 (54%) male and 23 (46%) female subjects. Not statistically significant differences (p = 0.162) in gender between patients groups and control group. The age groups proportion of in patients group ≤ 18 years 30 (37.5%), 19-40 years 31(38.8) and > 41years 19 (23.8%).in the control group the age proportion ≤ 18 years 17 (34.0%), 19-40 years 25(50.0%) and > 41years 8 (16.0%).The mean ages of the leukemia patients were (40.10±9.59) year, and the healthy control groups were (27.83±1.95) year, respectively. The result showed highly significant (p-value<0.05) increase in acute leukemia patients as compared control group in mean of PDGF-BB level (439.64±20.4 vs. 1183.4±23.91), ANXA level (22.44±0.15 vs. 6.69±0.32), D-Dimer level (0.32±0.02 vs. 0.68±0.03), H3 level (1.73±0.11 vs. 3.14±0.1). Figure (1) show no significant difference X2=3.200 (p=0.074) in the number of patients groups distribution percentage AML 32 (40%) and ALL 48 (60). The results in figure (2) show highly significant difference X2=8.450 (p=0.004) in the number of gender distribution between patients groups male 53 (66.3%) and female (27 33.8%). The proportions of age in patients groups show no significant X2=3.325 (p=0.190) difference in number of percentage ≤ 18 years 30 (37.5%), 19-40 years 31(38.8) and > 41years 19 (23.8%) show in figure (3). The statistical analysis showed in table (2) a significant difference (P<0.05) elevated means±SE in AML patients group of these parameters age, PDGF-BB level, ANXA2 level and D-Dimer level compared to the ALL patients group (39.09±2.83 years, 20.31±2.04y years), (1286.25±30.06, 1114.84±30.89), (8.36±0.53, 5.58±0.32) and (0.87±0.13, 0.56±0.03) respectively. In the same table the H3 level no significant (P>0.05) show in means±SE when compared AML group with ALL group (3.27±0.13, 2.98±0.14). The results of correlations observed that H3 level were no significantly positive correlated (p>0.05) with PDGF-BB level in ALL group (r=0.231, P=0.114), but the H3 level significantly positive correlated (p<0.05) with PDGF-BB level in AML group (r=0.405, P=0.021), figure (4). Also the results of correlations showed that H3 level were no significantly positive correlated (p>0.05) with ANXA2 level in ALL group (r=0.191, P=0.193), but the H3 level significantly positive correlated (p<0.05) with ANXA2 level in AML group (r=0.380, P=0.032), figure (5), while PDGF-BB level strong positive with D=Dimer level in ALL group (r=0.503, P=0.0001), PDGF-BB level and ANXA2 level in AML group (r=0.430, P=0.014), figure (6), H3 level have significantly positive correlated (p<0.05) with D-

RETRACTED

Dimer in ALL group (r=0.433, P=0.002) and AML group (r=0.376, P=0.034), figure (7), respectively. Through assessing the cut-off point for plasma biomarkers PDGF-BB, D-Dimer, ANXA2, and H3 levels to discrement the acute leukemia patients and controls. According the results that show in Table (3), and Figure (8) these were indecated to acute leukemia patients have a higly posative significant <0.05 predictive value of PDGF-BB level (AUC= 0.995, p=0.0001; cut-off value ≥ 583.3250 (pg/ml), sensitivity = 1.000; and specificity = 0.940), follwoed D-Dimer was (AUC= 0.950; p=0.0001, cut-off: ≥0.4550 mg/L, sensitivity =0.813 and specificity 0.940) respectively, more than ANXA2 (AUC= 0.933, cut-off value ≥4.3494 mg/L, p=0.0001, sensitivity=0.788 and specificity=0.940) and H3 (AUC= 0.880; cut-off value ≥ 2.5900 mg/L, p=0.0001with sensitivity = 0.738; and specificity = 0.880).

Table 1. Comparison demographic and clinic characteristics of acute leukemia patients and the healthy controls.

Variables	Control n=50	Acute leukemia Patients n=80	P-value
	Mean ±SE	Mean ±SE	
Age (year)	24.94±2.0	27.83±1.95	0.327
≤ 18 year **19-40 year** **> 41 year**	17 (34.0%) 25 (50.0%) 8 (16.0%)	30 (37.5%) 31 (38.8%) 19 (23.8%)	1.898 [a] 0.387 ns
Male **Female**	27 (54.0%) 23 (46.0%)	53 (66.3%) 27 (33.8%)	1.951 [a] 0.162 ns
PDGF-BB	439.64±20.4	1183.4±23.91	0.0001**
ANXA2	2.44±0.15	6.69±0.32	0.0001**
D-Dimer (µg/mL)	0.32±0.02	0.68±0.03	0.0001**
H3	1.73±0.11	3.14±0.1	0.0001**

Significant differences at p-value * <0.05, and ** <0.01. a chi-square and data expressed as frequencies and percentage. Ns: non- significant.



Fig. 1. Distribution patients groups of acute leukemia patients. Significant differences at p-value * <0.05, and ** <0.01. X2 :chi-square. ALL patients n= 48, AML patients n=32.

RETRACTED

RETRACTED



Fig. 2. Distribution of gender in acute leukemia patients groups. Significant differences at p-value * <0.05, and ** <0.01. X2:chi-square. ALL patients n= 48, AML patients n=32.



Fig. 3. Distribution of age in acute leukemia patients groups. significant differences at p-value * <0.05, and ** <0.01. X2 :chi- square. ALL patients n= 48, AML patients n=32.

Table 2. Comparison parameter characteristics between acute leukemia patients groups.

Variables	AML n=32	ALL n=48	p-value
	Mean ±SE	Mean ±SE	
Age (year)	39.09±2.83	20.31±2.04	0.0001**
PDGF-BB (pg/ml)	1286.25±30.06	1114.84±30.89	0.0001 **
ANXA2 (ng/ml)	8.36±0.53	5.58±0.32	0.0001 **
D-Dimer (μg/mL)	0.87±0.13	0.56±0.03	0.0001 **
H3 (ng/ml)	3.27±0.13	2.98±0.14	0.154 ns

Significant differences at p-value * <0.05, and ** <0.01.



Fig. 4. Posative correlation between plasma H3 (ng/ml) and PDGF_BB (pg/ml) levels in ALL (blue color) and AML (red color) patients.



Fig. 5. Posative correlation between plasma H3 (ng/ml) and ANXA2 (ng/mL) levels in ALL (blue color) and AML (red color) patients.



Fig. 6. Posative correlation between plasma PDGF_BB (pg/ml) and D-Dimer (mg/L) levels in ALL (blue color) and AML (red color) patients.



Fig. 7. Posative correlation between plasma H3 (ng/ml) and D-Dimer (mg/L) levels in ALL (blue color) and AML (red color) patients

RETRACTED

 https://doi.org/10.1051/bioconf/20248403020

Table 3. ROC curve for determine the important biomarkers to diagnostic between acute leukemia's patients (ALL, AML) and control groups

Variables	AUC	SE	p-value	95% CI	Cutoff	Sensitivity	Specificity
PDGF-BB(pg/ml)	0.995	0.004	0.0001**	0.988-1.002	≥583.3250	1.000	0.940
D-Dimer (mg/L)	0.950	0.016	0.0001**	0.917-0.982	≥0.4550	0.813	0.940
ANXA2	0.933	0.020	0.0001**	0.894-0.972	≥4.3494	0.788	0.940
H3	0.880	0.028	0.0001**	0.825-0.936	≥2.5900	0.738	0.880

Significant differences at p-value * <0.05, and ** <0.01. AUC: area under the curve. SE: standard error. 95%CI: confidence interval.



Fig. 8. Receiver operating curve characteristics (ROC) curves of PDGF-BB, D-Dimer, ANXA2 and H3 for diagnostic of acute leukemia disease in patients N=80 and control N=50.

4 Discussion

The results in table (1) showed mean ages of the acute leukemia patients were (40.10±9.59) year, and the healthy control groups were (27.83±1.95) year, respectively. The difference was not statistically significant (p = 0.378) because the ages of healthy subjects were chosen close to the ages of patients.

The results showed a considerable highly significant difference in most hematological parameters were expressed by PDGF, ANXA2, D-Dimer and when compared with control groups these were compatible with many studies have found due to disorders of blood-forming organs involving one or more cell-lines in the hematopoietic system. D-Dimer increase in acute leukemia means (13.01±0.09 vs. 15.48±0.18), (1.32±0.02 vs. 1.72±0.03), (32.93±0.38 vs. 37.02±0.32) respectively, Hemostatic complications due to coagulopathy is one of the leading causes of mortality in patients with acute leukemia [22].

The our study show highly elevated in PDGF-BB, ANXA2, and H3 levels in acute leukemia patients means (439.64±20.4 vs. 1183.4±23.91), ANXA (22.44±0.15 vs. 6.69±0.32) and H3 (1.73±0.11 vs. 3.14±0.1), respectively PDGF-B is stored in the α-granules of the platelets and is released in the platelet release reaction; therefore, an increase in plasma PDGF will reflect a state of platelet activation [23]. If a PDGF-B concentration was elevated to a standard value in healthy or normal controls, this indicates a presence or risk of developing thrombosis [24]. The increased level of PDGF in this study

RETRACTED

agrees with [25] found PDGF-BB level increase with acute leukemia specially AML. ANXA2 increase in acute leukemia patients, Annexin A2 provides an environment in which plasmin production in malignancy leads to an increased risk of thrombohaemorrhagic complications [26] our result mach with [27, 28]. Histones one of the main components of neutrophils extracellular traps (NETs) activate coagulation pathways and platelets [29, 30], its induce the release of the von Willebrand factor from endothelial Weibel–Palade bodies, which also contributes to thrombocytopenia [31]. In addition, histones promote thrombin generation and coagulation activation through platelet-dependent and platelet-independent mechanisms [32, 33]. Histones can increase TF activity and enhance thrombin generation in blood monocytes and endothelial cells [34, 35] therefore its elevated in acute leukemia patients this founding compatible with these studies [36, 37].

Table (2) showed most parameters (age, PDGF-BB, ANXA2, D-Dimer) have significant increase in AML group more than in ALL group, the age of AML group more than ALL group patients due to the AML occur in adult and older age the average age of diagnosis is age 68 this agreed with Wei et al., [38] founding, PDGF-BB level elevated in AML due to PDGF secreted from activated platelate that elevated in AML group this factor have role in TF releasing that enhance coagulated cascade this founding compatible with Wilcox et al., [39] the ANXA2 increase also in AML group annexin A2 (ANXA2) mediated coagulopathy\hyperfibrinolysis has been identified as a key-pathway and its [40]. Since complications due to coagulopathies are one of the major causes of morbidity and mortality in AML patients [41].A high D-dimer level strongly predicts symptomatic venous and arterial thrombosis in newly diagnosed AML. Thrombosis occurs in up to 10% of patients with newly diagnosed AML [42]. But the H3 level was not significant because it was elevated closed level in two groups

Through assessing the cut-off point for plasma biomarkers PDGF-BB, D-Dimer, ANXA2, and H3 levels to discrement the acute leukemia patients and controls. According the results that show in Table (3), and Figure (8) these were indecated to acute leukemia patients have a higly posative significant <0.05 predictive value of PDGF-BB level (AUC= 0.995, p=0.0001; cut-off value ≥ 583.3250 (pg/ml), sensitivity = 1.000; and specificity = 0.940), follwoed D-Dimer was (AUC= 0.950; p=0.0001, cut-off: ≥0.4550 mg/L, sensitivity =0.813 and specificity 0.940) respectively, more than ANXA2 (AUC= 0.933, cut-off value ≥4.3494 mg/L, p=0.0001, sensitivity=0.788 and specificity=0.940) and H3 (AUC= 0.880; cut-off value ≥ 2.5900 mg/L, p=0.0001with sensitivity = 0.738; and specificity = 0.880). PDGF-BB conceder the predictive value for diagnosis between acute leukemia patients and control duo to it was stored in the α-granules of the platelets and is released in the platelet release reaction; therefore, an increase in plasma PDGF will reflect a state of platelet activation the first step in coagulation interaction [23].

If a PDGF-BB concentration was superior to a standard value in healthy or normal controls, this indicates a presence or risk of developing thrombosis [24]. The levels of PDGF-B are a significantly higher concentration of more than 10%, preferably more than 20%, 30%, 40%, or 50%, in patients with VTE [43] so it was very sensitive parameter. PDGF identified as a novel VTE-associated plasma protein and need other studies of further investigation [44]

5 Conclusion

The result showed all biomarkers increase level in acute leukemia patients when compared with healthy groups also the most biomarkers increase level in AML groups more than ALL except H3 have closed level in two patients groups. Also the study founding the

RETRACTED

PDGF-BB conceder important predictive biomarker to diagnosis between ALL and AML patients groups.

Thanks To all staff of national oncology and hematology disease hospital in Al-Najaf Al-Ashraf Governorate

References

1. R.L. Bowman, L. Busque, & R.L. Levine, Cell stem cell, **22(2),** 157-170 (2018).
2. J.D. Khoury, E. Solary, O. Abla, Y. Akkari, R. Alaggio, J.F. Apperley, A. Hochhaus. Leukemia, **36(7),** 1703-1719 (2022).
3. F. Shahab, & F. Raziq. J Coll Physicians Surg Pak, **24(7),** 472-6 (2014).
4. JM. Bennett, D. Catovsky, MT. Daniel, G. Flandrin, DA. Galton, HR. Gralnick, et al. Br J Haematol **, 33:** 451(1976).
5. J. de la Serna, P. Montesinos, E. Vellenga, et al.. Blood; **111**: 3395-3402 (2008).
6. ITO, Takashi. Journal of intensive care, **2:** 1-9 (2014).
7. M. Nakahara , T. Ito , KI. Kawahara, M. Yamamoto, T. Nagasato, B. Shrestha, S.Yamada, T. Miyauchi, K. Higuchi, T. Takenaka , et al. PLoS One; **8(9):** e75961 (2013).
8. S.T. Abrams, N. Zhang, G. Wang, C. Toh -H. Blood ;**122**: 457 (2013).
9. T. Ito, M. Nakahara, Y. Masuda, S. Ono, S. Yamada, H. Ishikura, H. Imaizumi, C. Kamikokuryo, Y. Kakihana, I.Maruyama. J Intensive Care. **6:** 79 (2018).
10. Y. Alhamdi, ST. Abrams , Z. Cheng, S. Jing , D. Su, Z. Liu, S. Lane, I. Welters, G. Wang , CH. Toh. Crit Care Med**. 43(10):** 2094–103(2015).
11. KC. Wildhagen, MA. Wiewel, MJ. Schultz, J. Horn, R. Schrijver, CP. Reutelingsperger, van der Poll T, Nicolaes GA. Thromb Res ;**136(3):** 542–7 (2015).
12. S. Madoiwa, T. Someya, M. Hironaka, H. Kobayashi, T. Ohmori, J. Mimuro, ... & Y. Sakata. Thrombosis research, **119(2),** 229-240 (2007).
13. M.V. Christensen, C. K. Høgdall, K. M. Jochumsen, & E. V. Høgdall. journal of oncology, **52(1),** 5-18 (2018).
14. A. M. Alhabibi, D. M. Eldewi, M. A. A. Wahab, Farouk, N., El-Hagrasy, H. A., & Saleh, O. I. Journal of Research in Medical Sciences: the Official Journal of Isfahan University of Medical Sciences, **24** (2019).
15. D. Sakçi, M.B. Sayhan, S. A. L. T. Ömer & I. Dibirdik. Dicle Tıp Dergisi**, 49(1),** 1-11(2022).
16. I Pabinger, J Thaler, C Ay Blood., **122 (12)** , 2011-2018 (2013).
17. EJ. Libourel, CPW. Klerk, Y. van Norden, MPM. de Maat, MJ. Kruip, P. Sonneveld, B. Lowenberg, FWG. Leebeek. Blood. **128**: 1854–61. (2016). 10.1182/blood-2016-02-701094
18. CW. Freyer, A. Carulli, A. Ganetsky, et al. Leuk Lymphoma.; **61(9):**2200-2207 (2020).
19. D. R. Anderson,W. Stock, T.G. Karrison, & A. Leader, A. Blood Advances, **6(17),** 5146-5151(2022).
20. R. Telama, X. Yang, J. Viikari, I. Välimäki, O. Wanne & O. Raitakari. American journal of preventive medicine, **28(3),** 267-273 (2005).
21. L. M. Sullivan. Essentials of biostatistics in public health. Jones & Bartlett Learning (2017).

RETRACTED

22. J. De La Serna, P. Montesinos, E. Vellenga, C. Rayón, R. Parody, A. León, ... & M. A. Sanz. Blood, The Journal of the American Society of Hematology, **111(7),** 3395-3402 (2008).
23. S.Rezayani, T. Farazmandfar, M. Shahbazi. Egypt J Med Hum Genetics; **18:** 359–63 (2017).
24. S. Vedantham, G. Piazza, AK. Sista, NA. Goldenberg. J Thromb Thrombolysis; **41**: 68–80 (2016).
25. B. Foss, E. Ulvestad, & Ø. Bruserud. European journal of haematology, **66(6)**, 365-376(2001).
26. A. Falanga, T. Barbui. Haematologica ;**106**: 43 — 51 (2001).
27. Christensen, M. V., Høgdall, C. K., Jochumsen, K. M., & Høgdall, E. V. International journal of oncology, **52(1),** 5-18. (2018).
28. Y. Ding, Y. Dong, H. Lu, X. Luo, J. Fu, B. Xiu, ... & W. Zhang. Circular RNA profile of acute myeloid leukaemia indicates circular RNA annexin A2 as a potential biomarker and therapeutic target for acute myeloid leukemia (2020).
29. A. Carestia, L. Rivadeneyra, MA. Romaniuk, C. Fondevila, S. Negrotto, M. Schattner . Thromb Haemost **110**: 1035–45 (2013).
30. M. Nakahara, T. Ito, KI. Kawahara, M. Yamamoto, T. Nagasato, B. Shrestha, S. Yamada , T. Miyauchi, K. Higuchi, T. Takenaka, et al. PLoS One **8(9):** e75961 (2013).
31. A. Michels, et.al., J. Thromb. Haemost; **14:** 2274–2286. (2016). doi: 10.1111/jth.13493
32. C.T. Ammollo, F. Semeraro, J. Xu, N.L. Esmon, C.T. Esmon. J. Thromb. Haemost.**;9:** 1795–1803 (2011).
33. F. Semeraro, C.T. Ammollo, J.H. Morrissey, G.L. Dale, P. Friese, N.L. Esmon, C.T. Esmon. Blood J. Am. Soc. Hematol **118**: 1952–1961 (2011).
34. T. J., Gould, et.al., Shock: Injury, Inflammation, and Sepsis: Laboratory and Clinical Approaches, **46(6),** 655-662 (2016).
35. J.E.Kim , H.J.Yoo , J.Y. Gu, H.K. Kim. PLoS ONE; **11**: e0156763(2016).
36. K. Harada-Shirado, X.Wang, H. Mori, et al. Int J Hematol **111(03):** 378–387(2020).
37. H. Mori, S. Torii, & R. Virmani. State of the Art Surgical Coronary Revascularization, **21** (2021).
38. Wei, H. Andrew , et al. Blood, The Journal of the American Society of Hematology 135. **24** : 2137-2145 (2020).
39. Wilcox, N. Josiah, and F. Barbara. Blumenthal. The Journal of nutrition **125**. suppl_3: 631S-638S (1995).
40. JS. Menell , GM. Cesarman, AT. Jacovina, MA. McLaughlin, EA. Lev, KA. Hajjar. N Engl J Med **340(13):** 994–1004. (1999).10.1056/NEJM199904013401303
41. M. Yanada, T. Matsushita, M. Suzuki, H. Kiyoi, K. Yamamoto, T. Kinoshita, et al.. Eur J Haematol . **77(4):** 282–7 (2006).. 10.1111/j.1600-0609.2006.00711
42. E. J. Libourel, C.P. Klerk, Y. van Norden, M.P. de Maat, M.J. Kruip, P. Sonneveld, ... & F.W. Leebeek. Blood, The Journal of the American Society of Hematology, **128(14),** 1854-1861 (2016).
43. J. Xu, L. Xie, W. Guo. Clin Sarcoma Res. 8:15 (2018).
44. M. Bruzelius, MJ. Iglesias, MG. Hong, L. Sanchez-Rivera, B. Gyorgy, JC. outo, et al. Blood. **128:** e59–66 (2016).

RETRACTED